Physician profile
Nerissa D'Silva
NPI 1932696333
$31,119.20
in general payments reported to CMS, 2019-2025
22 companies · $3,466 in 2025
The $3,466 reported for 2025 was more than what 79% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $178 · 2022: $1,207 · 2023: $25K · 2024: $1,040 · 2025: $3,466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $25K · Food and Beverage: $3,197 · Consulting Fee: $1,446 · Education: $91.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $25,000.00 |
| Food and Beverage | $3,196.94 |
| Consulting Fee | $1,446.00 |
| Education | $91.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $25,445.32 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $2,508.78 | 2021-2025 | |
| Regeneron Pharmaceuticals, INC. | $1,000.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $448.70 | 2022-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $272.67 | 2022-2025 | Tezspire, Airsupra |
| Ars Pharmaceuticals Operations, INC. | $270.49 | 2025 | Neffy |
| Optinose US, INC. | $155.13 | 2024-2025 | |
| Csl Behring | $151.99 | 2024-2025 | Hizentra |
| Alk-Abello, INC | $145.11 | 2021-2022 | |
| Grifols USA, LLC | $142.54 | 2023-2025 | Xembify |
| Pfizer INC. | $100.00 | 2023 | |
| Itamar Medical INC | $76.12 | 2023 | Watchpatone |
| Medtronic, INC. | $73.52 | 2024-2025 | Novapak, Stealthstation S8 Platform, Nuvent |
| Amgen INC. | $71.64 | 2024-2025 | Tezspire |
| Hikma Pharmaceuticals USA | $56.99 | 2024-2025 | Ryaltris |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $49.80 | 2025 | Takhzyro |
| Organon LLC | $44.79 | 2025 | |
| Novartis Pharmaceuticals Corporation | $27.48 | 2025 | |
| Paratek Pharmaceuticals, INC. | $21.88 | 2025 | Xhance |
| Cycle Pharmaceuticals INC | $20.92 | 2025 | Sajazir |
| Olympus America INC. | $18.88 | 2024 | |
| Biocryst US Sales Co., LLC | $16.45 | 2023 | Orladeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nerissa D'Silva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.